Latarcibart

莱塔西拜单抗

Report date: 2026/04/16 20:00:17

Base Information

Drug NameLatarcibart

Drug Alias NameVGA-039VGA039

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionVitamin K-dependent protein S inhibitors

TargetsVitamin K-dependent protein S

Therapy Area/Indicationsvon Willebrand Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesSouth Africa +[10]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

China Registration ClassN/A

Inactive CompaniesN/A

Active Indicationsvon Willebrand Diseases

Inactive IndicationsN/A

ATC CodeN/A